
































Tumour genomic and microenvironmental heterogeneity as integrated predictors for prostate cancer recurrence: a retrospective study
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Clinical prognostic groupings for localized prostate cancers (CaP) are imperfect, with 30-50% of patients recurring after image-guided radiotherapy (IGRT) or radical prostatectomy (RadP). The aim of this study is to improve risk stratification with combined genomic and microenvironmental indices, to complement clinical prognostic factors.
Methods
Prognostic indices were developed in 126 low to intermediate-risk IGRT patients and validated in two cohorts of 154 and 117 RadP specimens from low to high-risk patients. We applied machine learning to the copy-number profiles of 126 pre-IGRT diagnostic biopsies to develop signatures that reflect clinico-diagnostic scenarios. Overall, four novel and independently prognostic models for biochemical relapse (BCR) were generated using DNA-based indices alone or in combination with intra-prostatic hypoxia, to test the complementarity of CaP genomics and tumour microenvironment. These indices were validated in two independent RadP cohorts. The primary endpoint is BCR 5-years after primary treatment.
Findings
Inter-patient heterogeneity in CaP clinical outcome is significant: at five years, the biochemical relapse rates were 30%, 25%, and 32% for the three cohorts. BCR was associated with indices of tumour hypoxia, genomic instability, and genomic subtypes based on multivariate analyses (MVA). Four CaP genomic subtypes were identified, and differed in five-year biochemical relapse-free rates from 47%-81%. Genomic instability is highly prognostic for relapse in both IGRT (MVA Hazard Ratio (HR)=4·5 (2·1-9·8), p=0·00013; area under the curve (AUC)=0·71) and RadP (MVA HR=2·7 (1·5-4·8), p=0·00090; AUC=0·57) CaP patients, and its effect is magnified by intra-tumoural hypoxia (HR=3·8 (1·7-8·7), p=0·013, AUC=0·67). A novel 100-loci DNA signature accurately classified treatment outcome in a validation cohort for 124 low-intermediate risk RadP patients (MVA HR=6·1 (2·0-19), p=0·0015; AUC=0·74). In independent cohorts, this signature identified low-high risk patients most likely to fail treatment within 18 months (MVA HR=2·9, (1·4-6·0), p=0·0039, AUC=0·72). This DNA-signature outperformed 23 published RNA-signatures for biochemical relapse.
Interpretation
This is the first cancer outcome study to integrate DNA- and microenvironment-based failure indices to robustly predict patient outcome. Patients exhibiting these aggressive features on biopsy should be entered into treatment intensification trials.
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Prostate cancer (CaP) is diagnosed in close to 900,000 men annually worldwide, with 250,000 CaP deaths each year.1 The majority of cases are localized cancers (T1-T4N0M0), which are stratified into low-, intermediate- and high-risk groups based on their relative prostate-cancer specific mortality (PCSM) rates.2 These clinical prognostic groups are based on pre-treatment prostate-specific antigen (PSA), biopsy-based pathologic Gleason scores (GS), and UICC-TNM staging descriptors, such as the National Comprehensive Cancer Network (NCCN) classification system.3 Low-risk patients (i.e. GS ≤ 6, PSA < 10 ng/mL, or T1-T2a) can be offered active surveillance, sparing them the toxicities of treatment. In contrast, intermediate- (i.e. GS 7, PSA 10-20 ng/mL, or T2b-c) and high-risk/locally-advanced (i.e. GS ≥ 8, PSA ≥ 20 ng/mL, or T3/4) CaP patients often undergo RadP or IGRT alone, or receive intensified regimens adding adjuvant androgen deprivation therapy (ADT), and/or novel systemic agents to prevent progression to metastatic, castrate-resistant prostate cancer (mCRPC). However there is imprecision with the use of treatment intensification for individual patients: 30-50% experience biochemical relapse despite RadP or IGRT.4,5 Furthermore, nearly 20% of intermediate-risk patients fail within 18 months of primary local therapy (i.e. rapid failure). This may be due to pre-existing occult metastatic disease, as rapid biochemical failure is a surrogate for PCSM.6,7 The basis of this inter-patient CaP clinical heterogeneity may involve patient-specific genomic or tumour microenvironmental characteristics and has not been clinically resolved.8,9
A signature to classify patients as potential responders or non-responders to local therapy would have great clinical utility if it was treatment-independent (i.e. effective for both IGRT and RadP patients) and could be performed on initial diagnostic biopsies. Such a signature could triage patients at greatest risk of failure into clinical trials for treatment intensification and justify potential added toxicity.7,10 DNA copy number alterations (CNAs) in PTEN, NKX3-1, MYC, and STAR are associated with adverse prognosis,11,12 and RNA-based gene signatures may differentiate indolent and non-indolent, lethal CaP.e.g.13-15 TMPRSS2:ERG fusion status does not predict prognosis after RadP or IGRT.16,17 Importantly, tumour cells exist within a heterogeneous tumour microenvironment with dynamic gradients of hypoxia that have been linked to metastatic potential.9,18 Indeed, CaP patients with hypoxic tumours rapidly fail treatment (e.g. within two years) following IGRT or RadP.19,20 To date, the interplay of genomic instability and tumour microenvironment in modulating treatment outcome has been unexplored.
We show that integrated approaches using pre-treatment genomic and microenvironmental profiling can explain observed clinical heterogeneity in localized CaP, and identify patient sub-groups likely to experience rapid failure following local therapy. These results set the stage for novel approaches to treatment intensification or de-intensification for localized CaP.
Methods
Training and Validation Patient Cohorts
Our training cohort for generation of biopsy-based signatures consisted of 126 pre-IGRT, clinically-staged, low- or intermediate-risk CaP patients, based on NCCN guidelines; full details are provided in the appendix pp 4, 11-12 and supplementary file 1.3 DNA was extracted from pre-treatment biopsies with at least 70% tumour cellularity as estimated by a pathologist, and a custom array was used to detect CNAs. 12 Intra-glandular measurements of partial oxygen pressure (pO2) were taken pre-radiotherapy using an ultrasound-guided transrectal needle-piezoelectrode.20 To validate our findings, we used CNA profiles from two cohorts of clinically-staged (i.e. comparable to pre-IGRT patients) low- to high-risk RadP patients (MSKCC cohort n=154; Cambridge cohort n=117; appendix p 5, 11-12).8 CNA profiles are defined relative to the hg19 human genome build.
Prognostic Indices
Four prognostic indices were developed and validated for prediction of BCR (full methodological details in appendix pp 6-9). The primary and secondary endpoints were BCR status at 5 years and at 18 months, respectively. First, unique genomic subtypes were identified using unsupervised hierarchical clustering. Second, the percentage of a patient’s genome harbouring CNAs (percent genome alteration; PGA) was used as a surrogate for genomic instability, and evaluated together with tumour hypoxia. Finally, supervised machine learning with a random forest21 was used to identify a CNA signature, which was compared to published RNA-based signatures.
Statistical Analysis
All bioinformatic and statistical analyses were done in the R statistical environment (v3·0·2). Prognosis for BCR was assessed at 18 months and at 5 years by the area under the receiver operator characteristic analysis (AUC), by C-index analysis, and by Cox proportional hazard regression models. Indices were modeled with univariate and multivariate analyses (MVA), with the latter correcting for GS and pre-treatment PSA (and clinical T stage when considering high-risk patients; appendix p 6). Full C-index analyses for each biomarker are shown in the appendix. Two-sided non-parametric tests with a significance threshold of 0·05 were used to compare patient subsets. Multiple-testing correction was applied with the Benjamini-Hochberg or Bonferroni method, as indicated. Throughout the paper, the 95% confidence intervals are presented after hazard ratios (HRs) and the inter-quartile range after medians.
Role of the funding source
The sponsors of the study had no role in study design, report writing or in data collection, analysis, or interpretation. All authors had full access to all study data; the corresponding author (RGB) had full responsibility for the decision to submit for publication.
Results
Cohorts
An overview of our approach to develop treatment-independent, integrated prognostic indices is shown in appendix pp 34-35. We use information derived from pre-IGRT biopsies (training/Toronto-IGRT cohort) and initially validated with public RadP specimens (validation/MSKCC cohort). A secondary independent cohort of 117 RadP specimens was obtained for further validation of putative biomarkers (validation/Cambridge cohort). The RadP cohorts were considered both separately and together (“Pooled RadP”). We focused on clinically-matched validation cohorts containing low- and intermediate-risk patients (“low+int”, n=210) which might require treatment intensification beyond local therapy alone, but also considered all patients with localized disease (who might be candidates for intensification or de-intensification; “full” validation cohort, n=271). The biochemical relapse-free rates (bRFR) of the three cohorts were broadly comparable (appendix pp 36-39). Pre-treatment PSA was prognostic in IGRT patients, while pre-treatment GS, T-category, and PSA were all prognostic in the full MSKCC and Cambridge cohorts.
Defining Four Genomic Subtypes of Localized Prostate Cancer
Our initial analyses showed that Toronto-IGRT and MSKCC cohorts showed extensive genomic heterogeneity, even for patients that were solely low- or intermediate-risk, or GS 6 or 7 (appendix pp 13, 40-43, supplementary file 2). The most recurrent CNAs in either cohort include 8p amplifications and 8q deletions, as well as deletions of 16q23·2 and 6q15 (harbouring MAF and MAP3K7), which have been observed in aggressive tumours (table 1).22 We then determined the frequency of CNAs (i.e. CNA recurrence) for a set of putative adverse prognostic genes, selected from our previous studies and the literature, in the Toronto-IGRT biopsies (appendix p 44 and supplementary file 3). Despite low- or intermediate-risk classification, 60% (76/126) of patients had CNAs in at least two adverse prognosis genes. This variability occurred across the genome (see PGA discussed below) and suggested that genomically-defined CaP subtypes might be obtained from biopsies.
Unbiased hierarchical clustering in the Toronto-IGRT cohort (appendix pp 45-46) revealed four subtypes with distinct genomic profiles: Subtype-1 (characterized by gain of chromosome 7); Subtype-2 (deletion of 8p and gain of 8q); Subtype-3 (loss of 8p and 16q); and Subtype-4 (“quiet” genomes). Subtypes 2 and 3 share many common genetic alterations (504 genes altered in >25% of patients in both subtypes), yet chi-squared tests revealed eight regions which differed significantly, including gain of 8q (c-MYC has the smallest p-value) in Subtype-2 and 16q deletion in Subtype-3 (appendix p 14). All four subtypes were confirmed in the MSKCC RadP cohort and were not associated with TMPRSS2:ERG fusion, GS, or T-category (appendix pp 15-17, 47-48).
In a pooled (Toronto-IGRT + MSKCC) low+int cohort analysis (n=250), the four genomic subtypes of localized CaP are associated with significantly different prognosis, even after adjustment for clinical variables (table 2, figure 1, appendix p 18; see appendix p 49 for individual cohort and full cohort analyses). The 5-year bRFRs ranged from 53% (Subtype-3) to 89% (Subtype-4). Interestingly, Subtype-1 appears to be characterized by increased relapse after 3 years, rather than increased risk at all times, but larger cohorts are required to clarify this finding. These subtypes are prognostic by 18 months (log-rank p=0·0024, low-int cohort), which is associated with increased PCSM.6,7 Indeed, in the Toronto-IGRT cohort, Subtype-2 is associated with overall survival (OS) (MVA HROS=4·2 (1·2-15), Wald p=0·03, appendix p 19).
Genomic Instability Is Prognostic In Curable Prostate Cancers
The excellent prognosis of “quiet” Subtype-4 suggested genome-wide instability might be prognostic in itself. Using the percentage of the genome showing a copy-number alteration (PGA) as a proxy for genomic instability, we observed inter-patient PGA variability ranging from 0-52% in the Toronto-IGRT cohort, 0-34% in the MSKCC cohort, and 0-28% in the Cambridge cohort. PGA was independent of GS, T-category, and PSA in all cohorts (figures 2A-C). Indeed, individual GS 6 tumours showed higher PGA than some GS 4+3 tumours, suggesting PGA refines biological description even in predominant pattern 4 tumours. As expected, PGA was elevated in patients with prognostic CHD1 deletions (appendix p 50).23 
We noted that PGA itself was strongly prognostic, independent of clinical covariates, as recently reported.24 Remarkably, every 1% increase in PGA led to a 5-8% decrease in bRFR (C-index 0·60-0·72, appendix pp 20-21). To classify the likelihood of clinical failure based on PGA, we set the upper tertile of 7·49% from the Toronto-IGRT cohort as the lower bound threshold, which efficiently stratifies patients treated with either IGRT (MVA HRBCR=4·5 (2·1-9·8), Wald p=0·00013) or RadP (e.g. pooled RadP low-int cohort MVA HRBCR=4·0 (1·6-9·6), Wald p=0·0024; figure 2D-E). These results are threshold-independent (appendix p 51). PGA stratifies patients at risk of rapid failure consistent with occult metastases, and indeed is elevated in the primary tumours of patients that developed metastases relative to those who did not and had a follow-up time of at least five years (median 9·2% (3·6-13) vs. 2·8% (0·33-6·8), p=0·0043 pooled Toronto-IGRT and MSKCC cohorts, two-sided Mann-Whitney U-test; figure 2F, appendix pp 52-54).
The median PGA differed significantly among our genomic subtypes, with Subtypes 1 and 4 having the highest (12% (8·9-16)) and lowest (1·3% (0·16-3·2)) median PGA (appendix p 55). After the addition of PGA to the multivariate Cox proportional hazard model for subtypes, only Subtypes 2-3 remained prognostic, suggesting that their prognostic ability stems from both specific genetic aberrations and general genomic instability (appendix p 18).
Synergy Between Genomic Instability and Microenvironmental Indices of Failure
Hypoxia is an important aspect of cancer metabolism and in itself can be prognostic in CaP.19,20 However, no study has simultaneously measured cancer-related genomic and tumour microenvironment indices to explore surrogacy versus synergy in stratifying patient outcome. As a first approach, we used three hypoxia RNA signatures that have been validated in other tumour types to estimate hypoxia within the pooled RadP mRNA cohorts (108 MSKCC patients and 110 Cambridge patients; appendix p 22).25-27 This is, to our knowledge, the first attempt to apply these signatures to predict CaP outcome. None of these signatures were univariately prognostic, nor were they related to GS, PSA, T-category, or PGA (appendix 56-59). However when we separated patients into four groups based on high vs. low PGA and high vs. low hypoxia values, we observed a reproducible and unique effect of hypoxia being additive to PGA for prognosis. Patients with high PGA and high hypoxia have the worst prognosis, whereas patients with high hypoxia alone (low PGA) responded well following RadP (figure 3A-C, appendix pp 23-24, 60-61).
To validate this provocative observation, we used the Toronto-IGRT cohort as the biobanking of frozen biopsies was completed with simultaneous and direct assessment of tumour hypoxia at the same intra-prostatic locale.20 This unique cohort therefore contained direct measurements of hypoxia denoted by patient-specific HP20 values (i.e. the percentage of oxygen measurements less than 20 mm Hg; appendix p 25).20 The median HP20 in our cohort was 81% (64-93%), and trended to an association with elevated bRFR (log-rank p=0·13, appendix p 62) consistent with the previous observation in a larger cohort that hypoxia was independently prognostic of IGRT outcome.20 Directly measured HP20 values were not related to the clinical covariates, genomic subtype, PGA, or with any individual CNA (figures 3D, appendix pp 63-65), supporting a unique role in prostate cancer tumour biology. We again found that patients with low PGA and low hypoxia had the best outcome (5-year bRFR=93%), while those with high PGA and high hypoxia had the worst (5-year bRFR=49%, figure 3E). Moreover, there was a statistically significant interaction between PGA and hypoxia (unadjusted HRBCR=3·8 (1·7-8·7), Wald p=0·013; appendix pp 26-27) when used as a combined prognostic index. Again, patients whose tumour solely showed hypoxia, but not PGA, fared relatively well following IGRT, suggesting cohorts of patients with high hypoxia and high PGA could benefit from treatment intensification.
A Novel Gene-Specific Prognostic Signature for Biochemical Relapse 
Given that specific genes (figure 1), general genomic instability (figure 2), and tumour microenvironment (figure 3) all play a role in determining patient prognosis, we postulated that a supervised machine learning approach would capture the complex and unknown interactions between genes underlying these phenomena. Using a random forest21 classifier trained on the Toronto-IGRT cohort, we developed a biopsy-driven prognostic signature that predicts biochemical failure and could guide clinical decisions prior to, and independent of, treatment (appendix pp 66-67). The resulting 100-loci (276 genes; supplementary file 4) DNA signature was validated in two independent cohorts (figure 4A-B). It was first verified in the independent low+int MSKCC cohort, where it predicted BCR with an AUC of 0·74. This is superior to clinical variables (p=0·01 vs. NCCN; table 2, appendix pp 28, 68-69). MSKCC patients classified as poor-prognosis have 5-year bRFR of 58% compared to 89% for those classified as good-prognosis, and this difference remains significant after adjustment for clinical covariates (MVA HRBCR=6·1 (2·0-19), Wald p=0·0015; appendix pp 29, 70). Importantly, our signature effectively identified patients at risk of relapse within 18-months in the full MSKCC cohort, despite not including any high-risk patients in the initial training cohort (MVA HRBCR=3·3, (1·1-10), Wald p=0·038). This early-failure effect was validated in a second independent Cambridge cohort (MVA HRBCR=2·8, (1·7-9·4), Wald p=0·050; appendix pp 30, 70). The signature is independent of clinical covariates and indeed shows promise in identifying candidates for both treatment intensification and de-intensification protocols as it can identify GS 7 patients that will fail within 18 months (HRBCR=2·8 (1·2-6·7), p=0·021) and was also highly prognostic for low-risk patients (AUC=0·97; appendix pp 71-75). Importantly, the signature identified patients that go on to develop metastasis (AUC=0·78; table 2, appendix p 76).
To underpin the potential use of our DNA signature, we observed that it exceeded 97% (970,000/1,000,000) of the empirical null distribution from randomly sampled gene-sets (appendix p 77). Our signature also outperformed 23 previously published RNA signatures for CaP-associated bRFR after training random forests with a cohort of 1299 low to high risk prostate cancer patients with mRNA microarray data, including 293 low to intermediate risk patients. Applying these trained forests to the 108 MSKCC patients with both mRNA and CNA information, revealed that our DNA-signature has the highest overall AUC (figure 4C-D, appendix pp 31, 78).
Most genes in the signature are altered at relatively low rates, with 56% (154/276) altered in fewer than 10% (39/397) of patients (appendix p 79). These results strongly support the use of multi-gene models, as our biopsy-based DNA-signature outperformed reported prognostic genes (appendix p 80). Signature regions are distributed across 14 chromosomes, and range by an order-of-magnitude in their importance to prediction-accuracy (appendix p 81). Interestingly, genes in these regions relate to lipid metabolism (appendix p 82).
We also found that the signature directly accounts for genomic instability (appendix pp 82-85). First, patients with Subtype-4 tumours have significantly lower Signature Risk Scores than the other subtypes (0·17 (0·0026-0·32) vs. 0·41 (0·31-0·61), p<0·0001, two-sided Mann-Whitney U-test). Secondly, PGA differs significantly between the classes predicted by the signature and can be estimated from the gene signature (Spearman’s correlation between whole-genome and signature-estimated PGA ρ=0·73; p<0·0001), thereby providing similar prognostic information. Importantly, signature-based estimates of PGA remain highly prognostic, and adding 30 genes (selected from the Toronto-IGRT cohort) improves PGA estimates in the validation cohorts (e.g. MSKCC: Spearman’s ρ=0·73 vs. 0·87; p<0·0001; appendix p 32). The HR of continuous PGA estimated from these 306 genes is identical to that of true PGA in the MSKCC cohort and nearly identical for the Cambridge cohort. Taken together, these results indicate that our treatment-independent, DNA prognostic signature measures genomic instability in addition to lipid metabolism pathways.
Discussion
Development of CaP biomarkers to guide disease management at the time of diagnosis is a difficult yet critical ongoing challenge, given the high rates of over-treatment and clinical relapse.28 Here we developed clinically-relevant prognostic indices using integrated tumour DNA and microenvironmental indices (prognostic indices are summarized in table 2 and survival rates in appendix p 33). Initial investigation in the Toronto-IGRT cohort consisting of 126 low- to intermediate-risk patients revealed striking genomic heterogeneity in the pre-treatment biopsies from these patients, and has implications for the discovery of driver mutations in CaP. No CNAs were recurrent in more than 47% of patients and the number of CNAs per patient ranged from 0 to 187. We were, however, able to identify independent molecular prognostic subtypes based on genome-wide CNA profiles in the Toronto-IGRT cohort. Including additional patients from the independent MSKCC cohort of low- and intermediate-risk CaP patients led to larger subtype sizes amenable to bRFR analyses, revealing statistically significant differences in patient outcome according to subtype. Our CNA-based signature (100 regions across 14 chromosomes), identifies patients which differ 6-times in bRFR, and patients at risk of failure within 18 months, all within the current clinical context of GS, T-category, and PSA. In particular, this signature is highly effective for low-risk patients, identifying those ineligible for active surveillance and providing additional assurance for those who are. For instance, if the DNA signature was used in clinic today, of 1000 patients diagnosed with localized disease, 144 patients would be offered more aggressive treatment (all signature-positive patients), and 650 would have the support for active surveillance instead of local treatment (low-int signature-negative patients) (appendix pp 86-91). 
Pre-clinical experimental work supports hypoxia generating a mutator phenotype and selecting for genetically unstable clones, along with an increased capacity for distant metastases.18 This metastatic phenotype is independent of local treatment and indeed hypoxia is a poor prognostic marker regardless of treatment modality; it is associated with both local relapse after IGRT and also biochemical failure and distant metastasis in patients receiving IGRT or RadP for prostate cancer.19,20 Now, we have also shown that simultaneous measurement of tumour hypoxia and genomic instability can improve the prognostic capability of a pre-treatment biopsy by marrying the independent biology of cancer genomics and the tumour microenvironment. It also suggests that the poor prognosis previously associated with hypoxiae.g.19,20 may have been related to genomic instability within a subset of these specimens, given that hypoxia itself was not associated with poor prognosis in the absence of heightened PGA. 
Cancer cell metabolism (increased glycolysis, high lactate, and hypoxia) is related to oncogene activation and tumor suppressor loss, and increased lipid and fatty acid synthesis have been associated with CaP progression.29,30 It is intriguing that our supervised machine learning approach led to a signature enriched for genes involved in lipid biology. Combined with the finding that constitutive activation of mTORC1 renders hypoxic cells dependent on exogenous desaturated lipids, our signature could represent abnormalities in cancer metabolism amenable to targeting of lipid synthesis.29-32 In addition, our signature efficiently captures the prognostic impact of PGA, a surrogate for genomic instability. Given that ADT has been shown to both improve oxygenation33 and reduce DNA repair34 in CaP, we speculate that such therapies targeting hypoxia and genomic instability may be effective in preventing clinical relapse. Patients flagged by our signature may benefit from patient-specific intensification with ADT or other systemic therapies to offset both local and systemic resistance, independent of primary treatment.
To our knowledge, this is the first report of biopsy-driven, DNA-based indices that predict prognosis in patients who received either IGRT or RadP as primary therapy for CaP. Compared to RNA abundance, DNA alterations may be less variable within intra-prostatic biopsies from dynamic tumour microenvironments, and more stable ex vivo during FFPE protocols. This suggests that our DNA signatures are robust for clinical application. As our training cohort was obtained prior to primary therapy, our study supports the characterization of complex indices reflecting inter-patient heterogeneity a priori, soon after diagnostic MRI- or trans-urethral ultrasound-guided biopsies. Indeed, we have recently shown that frozen biopsies are amenable to whole genome sequencing to evaluate intra-patient heterogeneity in genomic aberrations (unpublished data; Boutros et al.).
There are several caveats to this study. Using BCR as an end-point is sub-optimal compared to PSCM or time to metastasis. Nonetheless, our signature shows promise in discriminating patients with metastasis, and can identify patients that will experience BCR prior to 18 months, which is predictive for PCSM.6,7 Although the cohorts differ slightly in the distribution of clinico-pathologic factors, these differences neither altered treatment nor survival (Supplementary Figure 3, appendix p 39), making it very unlikely that this affects the interpretation of our results. Nevertheless, we do systematically stratify our analyses according to these factors when assessing prognostic markers. A subset of patients were treated with adjuvant treatment, however at this time we do not know how adjuvant treatment affects our signature performance. We will explore this in new cohorts of patients treated with IGRT or RadP +/- ADT, and assess whether the biomarker would become a predictive biomarker rather than solely a prognostic marker. 
From a technical perspective, despite different resolutions between the CNA platforms used for each cohort, the CNA indices developed in the Toronto-IGRT cohort validated in the RadP cohorts. The hypoxia probes measure global hypoxia within a prostate cancer locale, but do not measure intracellular hypoxia. As a result, the DNA is obtained from a large region relative to sites of hypoxia. In future studies we will characterize the DNA, RNA, and epigenetic profiles of foci within patients that orally receive pimonidazole prior to treatment to investigate the genomic-hypoxia prognostic relationship in finer detail. Finally, efforts are underway to reduce the signature size without losing prognostic information related to metabolism or genomic instability, and to improve the sensitivity of our signature with multimodal data sets (e.g. combined DNA, RNA and epigenetic analyses) emerging from TCGA and ICGC studies.




Table 1: Most recurrently aberrant regions
Cytobands were assessed for recurrence in the Toronto-IGRT and MSKCC cohorts. The most important genes in the region are highlighted, based on the number of CNAs, or known association with CaP.
Table 2: Biomarker summary
Prognosis of proposed biomarkers and clinical variables. PGA: Percent Genome Alteration; AUC: Area Under the receiver operator Curve; HR: Hazard Ratio
a) The HR and p values (“HR (p)”) from Cox proportional hazard models are shown for each prognostic clinical variables in the univariate and multivariate setting for each full cohort. Multivariate models include Gleason Score, PSA and T-category only (NCCN is not included). The multivariate models show the covariates and levels used for multivariate analysis of biomarkers throughout the study.
* PSA is stratified at 10ng/mL since it fails the proportional hazards assumption.
**For the Toronto-IGRT cohort where there are only low-int patients, we compare T2 to T1 patients, whereas for the RadP cohorts, T3 patients are compared to T1-2 patients.
b) The HR and p-value are provided for dichotomized and continuous PGA in each cohort, based on Cox proportional hazard models including only the marker of interest (“Univariate”) and models including relevant clinical covariates as in the multivariate models in table 2A (“Multivariate”). The AUC and C-index are provided for the continuous PGA values.
c) HR, p-values, AUC, and C-index values for patients stratified by PGA and hypoxia. The Cox proportional hazard model was fit with four levels (PGA/Hypoxia: +/+, +/-, -/+, and -/-), with -/- patients used as the baseline group. Hazard ratios are not adjusted for clinical variables and the pooled RadP cohorts are shown for all three RNA hypoxia signatures.




Figure 1: Prognostic copy number subtypes of low to intermediate risk CaP
 Genomic subtypes have significantly different biochemical relapse rates in patients with low- to intermediate-risk disease treated by IGRT or RadP (MSKCC). Patients classified as Subtype-4 have a statistically better prognosis compared to the other subtypes. The log-rank p-value is displayed. See also appendix pp 15-19, 43-49.
Figure 2: Genomic instability (PGA) is an independent prognostic factor in CaP
PGA (percent genome alteration) is not a proxy for Gleason grade (a), clinical T group (b), or PSA (c) (n=336, Toronto-IGRT, MSKCC, and Cambridge low-intermediate NCCN risk groups combined). P-values were obtained by two-tailed Kruskal-Wallis tests (a) and Mann-Whitney tests (b-c). The black horizontal lines demonstrate the median PGA value per group. d) Kaplan-Meir analysis showing high PGA (upper tertile; 7.49%) is independently prognostic for biochemical failure in IGRT patients (n=126, Cox proportional hazard model; adjusted for Gleason score and pre-treatment PSA). e) Similarly, high PGA is independently prognostic for treatment failure in patients treated with RadP (pooled RadP full cohorts, n=271; Cox proportional hazard model adjusted for Gleason score and pre-treatment PSA). See also appendix pp 20-21, pp 50-55.
Figure 3: Integrating genomics and tumour microenvironment improves prognosis predictions for individual patients
Combining genome instability (PGA) and hypoxia within the same patient has an additive and independent prognostic effect, when measuring tumour hypoxia with the a) Buffa, b) West, or c) Winter RNA signatures in the pooled RadP full cohorts (n=271). See appendix pp 6, 22-24, and 56-61 for further details on RNA signatures and analyses. d) There is no correlation (Pearson (R) and Spearman (ρ) shown) between PGA and HP20. e) Combining genomic instability (PGA) and hypoxia (HP20) within the same patient has a multiplicative and independent prognostic effect in IGRT patients. PGA can further stratify patients with high hypoxia (HP20) such that those patients which also have PGA above the median have worse prognosis than patients with either elevated PGA or elevated HP20 alone or neither. A Cox proportional hazard regression model with PGA and hypoxia revealed that the interaction between these two terms is significant (appendix p 26-27). The log-rank p-value is shown. See also appendix pp 62-65.
Figure 4: A prognostic DNA signature for CaP
Patients whose tumour genomics are positive (Signature +) or negative (Signature -) for the 100-loci DNA signature derived in the Toronto-IGRT biopsy training cohort have different biochemical relapse rates RadP (pooled low+int validation cohort). a) The signature identifies low- to intermediate-risk patients (n = 210) at significantly higher risk of bRFR and is prognostic in a multivariate Cox proportional hazard model adjusting for clinical covariates (GS score and pre-treatment PSA). b) When applied to the full pooled RadP cohort (n = 271) the CNA-signature identifies patients that will fail rapidly (<18 months; a surrogate for PCSM6,7); the results are significant on multivariate testing when controlled for clinical covariates. See also appendix pp 28-30, 68-77.
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AUC: Area Under the Curve
PCSM: Prostate Cancer-Specific Mortality
PSA: Prostate Specific Antigen
GS: Gleason Score
NCCN: National Comprehensive Cancer Network
ADT: Androgen Deprivation Therapy
mCRPC: metastatic, Castrate-Resistant Prostate Cancer
CNA: Copy Number Alteration
pO2: partial Oxygen pressure
PGA: Percent Genome Alteration
bRFR: biochemical Relapse-Free Rate
OS: Overal Survival
HP20: percentage of oxygen measurements less than 20 mm Hg
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